Roth Capital raised the firm’s price target on Stryker (SYK) to $456 from $405 and keeps a Buy rating on the shares. The company’s Q1 earnings quality was good with strong gross margins, while the management’s stronger organic sales outlook, operating leverage, and better than expected FX easily offset an expected $200M impact from tariffs in 2025, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Stryker’s Strong Q1 2025 Performance and Resilience Justify Buy Rating Despite Tariff Challenges
- Stryker Corp Reports Strong Q1 2024 Earnings Growth
- Closing Bell Movers: Apple and Amazon slip after earnings
- Stryker sees FY25 adjusted EPS $13.20-$13.45, consensus $13.45
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue